Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Xcel Energy Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Xcel Energy Inc trades at $73.99 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 3.6× Halozyme Therapeutics Inc. Common Stock's market cap, and Xcel Energy Inc pays a 3.23% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Xcel Energy Inc for 61 Days on average.
| HALO | XEL | |
|---|---|---|
Market Cap | $12.58B | $45.82B |
Volume | 2,179,278 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $115.22 | $83.91 |
52-Week Low | $61.63 | $69.39 |
Typical Hold Time | 1 Days | 61 Days |
Enterprise Value | $14.49B | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Xcel Energy (XEL) trades at $73.78, up 1.87% with bullish technical signals and strong institutional support. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent earnings beats. Recent news highlights growing data center power demand and a $60B capital investment plan driving future growth. Analyst consensus remains positive with a $90.83 price target representing 23% upside potential.
XEL offers attractive total return potential through earnings growth and dividend yield, supported by regulated utility business model and infrastructure investments. Key risks include wildfire liabilities, rising interest rates impacting financing costs, and execution challenges with large capital projects. The stock presents a balanced opportunity for income and growth investors seeking utility exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
